Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 11, Issue 12, Pages 1587-1609Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.11.12.1587
Keywords
antisense inhibitor; B-Raf; cancer; c-RAF-1; combination therapy; epidermal growth factor; kinase inhibitor; MEK; Ras; signal transduction; systems biology
Categories
Funding
- NCI NIH HHS [R01 CA063366-12, R01 CA063366-08, R01 CA063366-07, R01 CA063366-13, R01 CA113342-01A2, R01 CA063366, R01 CA113342, R01 CA063366-11, R01 CA113342-02, R01 CA063366-09, R01 CA063366-06, R01 CA63366, R01 CA063366-10A2, P30 CA006927, R01 CA063366-14A1] Funding Source: Medline
Ask authors/readers for more resources
Over the past 5 years, the Raf kinase family has emerged as a promising target for protein-directed cancer therapy development. The goal of this review is to first provide a concise summary of the data validating Raf proteins as high-interest therapeutic targets. The authors then outline the mode of action of Raf kinases, emphasizing how Raf activities and protein interactions suggest specific approaches to inhibiting Raf. The authors then summarize the set of drugs, antisense reagents and antibodies available or in development for therapeutically targeting Raf or Raf-related proteins, as well as existing strategies combining these and other therapeutic agents. Finally, the authors discuss recent results from systems biology analyses that have the potential to increasingly guide the intelligent selection of combination therapies involving Raf-targeting agents and other therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available